SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 19, 2003
CRYOLIFE, INC.
(Exact name of registrant as specified in its charter)
Florida
(State or other jurisdiction of incorporation)
1-13165 59-2417093
(Commission File Number) (IRS Employer Identification No.)
1655 Roberts Boulevard N.W., Kennesaw, Georgia 30144
---------------------------------
(Address of principal executive offices, including zip code)
(770) 419-3355
---------------------------------
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.
On August 19, 2003 and August 20, 2003, respectively, CryoLife, Inc.
("CryoLife") issued press releases relating to the appointment of Thomas J.
Lynch, J.D., Ph.D., as Vice President of Regulatory Affairs & Quality Assurance,
and Gregory Ray, M.D., as Associate Medical Director. CryoLife hereby
incorporates by reference herein the information set forth in its Press Releases
dated August 19, 2003 and August 20, 2003, respectively, copies of which are
attached hereto as Exhibits 99.1 and 99.2.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
Exhibit Number Description
-------------- -----------
99.1 Press Release dated August 19, 2003
99.2 Press Release dated August 20, 2003
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
CRYOLIFE, INC.
Date: August 21, 2003 By: /s/ D. Ashley Lee
--------------------------------------
Name: D. Ashley Lee
Title: Vice President, Chief Financial
Officer and Treasurer
3
EXHIBIT INDEX
Exhibit Number Description Page
- -------------- ----------- ----
99.1 Press Release dated August 19, 2003 5
99.2 Press Release dated August 20, 2003 7
4
EXHIBIT 99.1
[COMPANY LOGO]
CRYOLIFE(R) NAMES THOMAS J. LYNCH, J.D., PH.D., VICE PRESIDENT, REGULATORY
AFFAIRS AND QUALITY ASSURANCE
ATLANTA, Aug. 19 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced
today that Thomas J. Lynch, J.D., Ph.D., has been appointed Vice President,
Regulatory Affairs and Quality Assurance. He will report to Steven G. Anderson,
President and CEO. Dr. Lynch will oversee the Company's Regulatory Affairs and
Quality Assurance operations and will be responsible for compliance with
legislative and regulatory requirements.
Dr. Lynch joins CryoLife from Clearant, Inc., a leader in pathogen inactivation
(sterilization) for biological products, where for the past three years he was
the Senior Vice President, Regulatory Affairs and Quality Assurance, responsible
for developing and implementing improved safety processes and procedures for new
and existing biopharmaceutical products. Before joining Clearant, Dr. Lynch
served as deputy director for the U.S. Food and Drug Administration (FDA)
Division of Hematology, Office of Blood Research and Review, Center for
Biologies Evaluation and Research. He worked at this division of the FDA for six
years, where he was involved in new product review and approvals, and in
regulatory compliance. Prior to that, he worked as a research scientist in
several positions in academia, at the National Institutes of Health (NIH), and
the Biotech industry.
"Tom's extensive experience and knowledge will be a great benefit to CryoLife
and I am confident that he will contribute to our future successes," Anderson
said. "He will play a key role in our organization and his leadership will be
instrumental in helping to move the Company's regulatory and quality assurance
initiatives forward."
Dr. Lynch holds a doctorate in biochemistry from Wayne State University, and a
Law degree from Georgetown University.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution
of implantable living human tissues for use in cardiovascular and vascular
surgeries throughout the United States and Canada. The Company's BioGlue(R)
Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use
in adult patients in open surgical repair of large vessels and is CE marked in
the European Community and approved in Canada for use in soft tissue repair and
approved in Australia for use in vascular and pulmonary sealing and repair. The
Company also manufactures the SynerGraft(R) Vascular Graft, which is CE marked
for distribution within the European Community.
5
For additional information about the company, visit CryoLife's web site:
http://www.cryolife.com .
Contact: Joseph T. Schepers
Vice President, Corporate Communications
(770) 419-3355
Rosa Herrera
Fleishman Hillard
(404) 739-0153
6
EXHIBIT 99.2
[COMPANY LOGO]
CRYOLIFE(R) NAMES GREGORY RAY, MD ASSOCIATE MEDICAL DIRECTOR
ATLANTA, Aug. 20 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced
today that Gregory Ray, M.D., a board certified pathologist, has been appointed
Associate Medical Director. Dr. Ray will report directly to J. Robin de Andrade,
M.D., Medical Director. Dr. Ray will be responsible for establishing Cryolife's
in-house pathology laboratory, which will work closely with the Quality
Assurance department. Dr. Ray will also provide expertise in determining
suitability of donors and tissues and will interact with tissue procurement
organizations and medical examiners.
Dr. Ray joins CryoLife from Pathworks Anatomic Laboratory where he has worked
since 2000 and served most recently as medical director. Dr. Ray also worked for
the Georgia Bureau of Investigation, Division of Forensic Sciences, Emory
University School of Medicine and North Lake Medical Center.
"Gregory is highly and uniquely qualified to establish our pathology lab as well
as coordinate activities with procurement organizations and medical examiners,"
said J. Robin de Andrade, M.D., CryoLife's Medical Director. "His experience
will help us work toward increasing the efficiency and timeliness of the
Company's tissue processing."
Dr. Ray received a B.S. from Oglethorpe University, and an M.D. from the Medical
College of Georgia and completed residence training in pathology and laboratory
medicine at Emory University.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution
of implantable living human tissues for use in cardiovascular and vascular
surgeries throughout the United States and Canada. The Company's BioGlue(R)
Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use
in adult patients in open surgical repair of large vessels and is CE marked in
the European Community and approved in Canada for use in soft tissue repair and
approved in Australia for use in vascular and pulmonary sealing and repair. The
Company also manufactures the SynerGraft(R) Vascular Graft, which is CE marked
for distribution within the European Community.
For additional information about the company, visit CryoLife's web site:
http://www.cryolife.com.
Joseph T. Schepers Rosa Herrera
Vice President, Corporate Communications Fleishman Hillard
770) 419-3355 (404) 739-0153
7